10-K: iSpecimen Inc. Reports Annual Results for Fiscal Year 2024, Cites Going Concern Uncertainty

iSpecimen Inc.'s annual report reveals a net loss of $12.5 million for 2024 and raises substantial doubt about the company's ability to continue as a going concern.

Summary

• iSpecimen Inc. reported a net loss of $12,497,805 for the fiscal year ended December 31, 2024, compared to a net loss of $11,099,488 in 2023.
• The company's accumulated deficit as of December 31, 2024, was $71,862,617.
• There is substantial doubt about iSpecimen's ability to continue as a going concern due to recurring net losses and accumulated deficits.
• Revenue decreased by 6% to $9,291,115 in 2024 from $9,928,184 in 2023.
• The company identified a material weakness in its internal control over financial reporting related to sales tax obligations.
• iSpecimen is implementing remediation measures to address the material weakness, including engaging external tax advisors and implementing a sales tax software platform.
• The company's supply network consisted of approximately 76 unique healthcare organizations and biospecimen providers as of December 31, 2024.
• As of December 31, 2024, iSpecimen had distributed specimens to approximately 765 customers across 23 countries.
• One customer accounted for approximately 29% of the company's total revenue in 2024.
• The company is subject to various risks, including the need for additional capital, reliance on a few customers, and potential regulatory changes.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to recurring losses, going concern uncertainty, and a material weakness in internal control. While there are some positive aspects, such as remediation efforts and a diverse customer base, the overall tone is concerning from an investment perspective.

Positives

• iSpecimen is implementing remediation measures to address the material weakness in internal control.
• The company has a broad supply network of 76 healthcare organizations and biospecimen providers.
• iSpecimen has a diverse customer base, distributing specimens to approximately 765 customers across 23 countries.
• The company has federal net operating loss carryforwards (NOLs) of approximately $62.40 million as of December 31, 2024.
• The company is implementing a next day quote system which has increased conversion ratios of quotes to purchase orders of 41%.

Negatives

• iSpecimen incurred a net loss of $12.5 million in 2024 and has an accumulated deficit of $71.9 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• Revenue decreased by 6% in 2024.
• A material weakness in internal control over financial reporting was identified.
• The company relies on a few customers for a significant portion of revenue.
• The company is required to open a dedicated bank account by April 20, 2025 and deposit 15% of revenue starting one month after the account opening up to $420,000 related to a legal proceeding.

Risks

• The company may require additional capital in the future, and an inability to meet future capital needs could adversely impact its ability to operate.
• The company's revenue trend is not predictive, which can lead to difficulty in accurately forecasting future results.
• International operation expansion could expose the company to additional risks.
• If the company's security measures are breached, its platforms may be perceived as not being secure.
• Changes in demand for the company's products and services could affect profitability.
• The company relies upon relatively few customers for a significant portion of revenue.
• The adoption cycle of the company's supply network tends to be very lengthy.
• Potential adverse effects from changes in the healthcare industry could affect access to subjects, samples, and data.
• The company does not control the end-to-end quality of specimens and data collected in its supply chain.
• The company may lose business to competitors which have or develop their own biorepositories and/or collection centers.
• The company may incur additional debt, which may restrict its operations and ability to make investments and distributions.
• The company does not have any patents protecting its intellectual property.
• Failure to comply with federal and state data protection regulations could result in fines, penalties, and litigation.
• There can be no assurance that an active and liquid trading market for the company's common stock will continue.
• The sale of substantial shares of the company's common stock may depress its stock price.
• The company does not expect to pay dividends in the foreseeable future.
• The company's directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of its other stockholders.

Future Outlook

The company plans to improve its sales and revenues, reduce and manage expenditures, and generate additional revenues through revenue enhancement projects. However, there is no assurance that the company will be successful in completing any of these options.

Management Comments

• Executive management of the Company continues to review the Companys structure, processes, and resources to evaluate and identify areas for improvement, and has been focused on creating and ensuring a runway for growth and scale for the business.
• We believe that our business will continue to be resilient through a continued industry-wide economic slowdown in life science research, and that we will continue to work on improving our liquidity to address our financial obligations and alleviate possible adverse effects on our business, financial condition, results of operations or prospects.

Industry Context

iSpecimen operates in a highly fragmented landscape of organizations who have access to human biospecimens, including healthcare providers, commercial biobanks, specimen brokers, and research services marketplaces. The company faces increasing competition, especially from larger biospecimen providers who are consolidating the industry through mergers and acquisitions.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, it mentions competitors such as Discovery Life Sciences and StemExpress, which maintain internal biobanks and enable researchers to search online for specimens within their own biobanks.
• It also mentions Science Exchange, which allows researchers to describe a specimen request which then gets broadcast to a network of specimen providers.

Management Changes

Legal Proceedings

• On December 9, 2024, Focus Technologies, Inc. filed a complaint against the Company alleging non-payment under agreements dated July 29, 2022, related to the provision of information technology services.
• On April 10, 2025, the Court partially granted Focus Motion for Pre-Judgment Security.
• On January 30, 2025, the Company signed a settlement agreement pursuant to the existing legal matter brought by the Companys former Chief Information Officer, Benjamin Bielak.

Stakeholder Impact

• Shareholders: The company's financial performance and going concern uncertainty may negatively impact shareholder value.
• Employees: The company has implemented reductions in workforce to decrease capital and operational expenditures.
• Customers: The company is focused on providing high-quality products and services to its customers.
• Suppliers: The company is shifting its focus from high volume to high value suppliers.

Next Steps

• The company plans to improve its sales and revenues.
• The company plans to reduce and manage expenditures.
• The company plans to generate additional revenues through revenue enhancement projects.
• The company is in the process of implementing a remediation plan to improve its internal control over financial reporting.

Key Dates

Keywords

biospecimens, iSpecimen, revenue, marketplace, research, specimens, data, customers, suppliers, technology